For clinicians who adjust a therapy over months, not in one visit. Proteox tracks how your patient's plasma protein profile shifts over time, against their own baseline, so you see the biological effect of a therapy and adjust it on evidence, not only on symptoms.
A single blood test cannot tell you what a treatment did. Most proteins vary far more between people than within one person, so one result held against a population range hides whether your patient moved, in which direction, and by how much.
Proteox reads a series of draws against your patient's own baseline instead: ~3,000 plasma proteins each time, not a handful of routine markers. The dose can then follow the measured biological response, not only the symptoms.
~3,000 plasma proteins from a standard venous draw, processed by accredited partner laboratories.
Same platform, same protocol, every draw.
Which of your patient's proteins and pathways changed beyond measurement and biological noise, and which did not. Context from the UK Biobank Pharma Proteomics Project (~54,000 individuals).
Plasma proteomics has reached population scale. For the first time, thousands of proteins can be followed in one person, draw after draw. That changes the question we can ask.
Every protein drifts in the same person even when nothing has happened. Proteox measures that drift, so a reported change is one your patient does not produce by chance. Two things make this possible.
Estimated protein by protein, so the threshold for a real change is specific to each protein, not one cut-off for the whole panel.
UK Biobank Pharma Proteomics Project data (~54,000 individuals, ~3,000 proteins) shows where your patient sits, and how unusual a change is.
You run long-course therapies, hormone and metabolic among them. We give you each patient's measured biological response, from the first draw, alongside the monitoring you already do.
You study treatment response or intervention effects in longitudinal designs. We give you an analytical framework built for within-person questions.
You need pharmacodynamic readouts across a trial or a real-world cohort. We give you the proteomic analysis, on established, accredited platforms.
Proteox Ltd is a UK company founded in 2025, operating from Bilbao, Spain and the UK.
We do not run a laboratory. Measurements run on established, accredited platforms through partner laboratories. A clinic adds no new lab; we add no new assay.
Our work is the design, the reference framework and the interpretation.
We report what the data support, and we publish our methods.
We are working with a small number of founding clinical partners. If you run a clinic, a research group or a pharma programme where within-person proteomic monitoring fits, write to us.
pablo@proteox.com